n(g),n(g')-dimethyl-l-arginine has been researched along with Kidney Failure, Chronic in 124 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients." | 7.77 | Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. ( Boger, R; Maas, R; Malatino, L; Mallamaci, F; Mattace Raso, F; Rapisarda, F; Seck, MS; Sijbrands, E; Tripepi, G; Witteman, J; Zoccali, C, 2011) |
| "Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) recently were recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related." | 7.73 | Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. ( Hishida, A; Ikegaya, N; Kato, A; Kumagai, H; Maruyama, Y; Sakurai, M; Takita, T; Uno, S, 2006) |
| "In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions." | 5.35 | Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. ( Bode-Boger, SM; Csiky, B; Lakatos, O; Martens-Lobenhoffer, J; Sulyok, E; Wittmann, I, 2008) |
| "Coadministration of intravenous methylcobalamin and oral folate in hemodialysis patients normalized hyperhomocysteinemia and decreased ADMA levels and arterial stiffness." | 5.14 | Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. ( Dohi, Y; Ito, A; Itoh, T; Kajikuri, J; Koyama, K; Kumagai, H; Nakamura, H; Nishio, T; Ohte, N; Sano, A; Yamamoto, J, 2010) |
| "Patients with essential hypertension (n = 24) were administered a low-salt diet (2 g NaCl/day), a high-salt diet (20-23 g) and then a low-salt diet for 7 days, and plasma levels of nitrate and nitrite (NOx) and asymmetric dimethylarginine (ADMA) were examined." | 5.10 | Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. ( Fujiwara, N; Nakamura, M; Okumura, K; Osanai, T; Osawa, H; Saitoh, M; Sasaki, S; Tomita, H; Yamabe, H, 2002) |
| " Thus, together with classic risk factors such as hypertension, dyslipidemia and diabetes, other situations such as microinflammation, increased concentration of asymmetrical dimethyl-L-arginine, disturbed phosphate metabolism and anemia may represent important risk factors for accelerated atherosclerosis in dialyzed patients." | 4.82 | Atherosclerosis in dialyzed patients. ( Ritz, E, 2004) |
| "We review the role inflammation [C-reactive protein (CRP)], hyperhomocysteinemia, high plasma norepinephrine, and accumulation of the endogenous inhibitor of the nitric oxide synthase asymmetric dimethylarginine (ADMA) in the high all-cause and CV mortality of patients on continuous ambulatory peritoneal dialysis (CAPD)." | 4.82 | Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. ( Enia, G; Mallamaci, F; Panuccio, V; Tripepi, G; Zoccali, C, 2005) |
| "We aimed to evaluate oxidative stress [8-hydroxydeoxyguanosine (8-OHdG), malondialdehyde (MDA)] endothelial damage [asymmetric dimethylarginine (ADMA)] and markers of cellular inflammation [interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), neopterin (NP) and high-sensitivity C-reactive protein (hsCRP)] in patients with diabetic nephropathy (DN) and non-diabetic nephropathy who were being administered hemodialysis treatment because of chronic renal failure." | 3.80 | Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. ( Agilli, M; Avci, E; Bilgi, C; Cakir, E; Cevher, SC; Yaman, H, 2014) |
| " We found that mild hypertension, increased plasma levels of creatinine, inorganic phosphate, asymmetric dimethylarginine (ADMA), and parathyroid hormone (PTH) were observed in the present SNx rats without LVH." | 3.77 | Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. ( Aizawa, K; Ishizuka, N; Iwabuchi, S; Kitamura, H; Moriguchi, Y; Nishimura, T; Serizawa, K; Tashiro, Y; Yogo, K; Yorozu, K, 2011) |
| "Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients." | 3.77 | Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. ( Boger, R; Maas, R; Malatino, L; Mallamaci, F; Mattace Raso, F; Rapisarda, F; Seck, MS; Sijbrands, E; Tripepi, G; Witteman, J; Zoccali, C, 2011) |
| " Covariates that were considered for adjustment included clinical characteristics, baseline GFR (Modification of Diet in Renal Disease equation 7 formula), proteinuria, traditional cardiovascular risk factors, serum C-reactive protein, homocysteine, and concomitant therapies." | 3.73 | Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. ( Malberti, F; Mallamaci, F; Ravani, P; Testa, S; Tripepi, G; Zoccali, C, 2005) |
| "In a cohort of 246 dialysis patients without heart failure at baseline we tested the combined prognostic power of three well-established biomarkers: brain natriuretic peptide (BNP), C-reactive protein (CRP), and asymmetric dimethyl arginine (ADMA)." | 3.73 | Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. ( Cutrupi, S; Malatino, LS; Mallamaci, F; Tripepi, G; Zoccali, C, 2005) |
| "Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) recently were recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related." | 3.73 | Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. ( Hishida, A; Ikegaya, N; Kato, A; Kumagai, H; Maruyama, Y; Sakurai, M; Takita, T; Uno, S, 2006) |
| "We investigated whether the eNOS G/T polymorphism (Glu298Asp variant) is linked to the severity of carotid atherosclerosis and whether it is independent of asymmetric dimethylarginine (ADMA) in determining vascular damage in patients with end-stage renal disease (ESRD)." | 3.73 | Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. ( Benedetto, FA; Boeger, RH; Maas, R; Mallamaci, F; Parlongo, RM; Pisano, A; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2005) |
| "Treatment with febuxostat resulted in a significant decrease in the serum ADMA level from 1." | 2.84 | Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study. ( Alshahawey, M; Elsaid, TW; Sabri, NA; Shahin, SM, 2017) |
| "Ramipril did not increase ADMA levels in a study of patients without ESRD, suggesting that factors related to ESRD or hemodialysis contribute to the ACE inhibitor-induced increase in ADMA." | 2.80 | Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study. ( Brown, NJ; Gamboa, JL; Ikizler, TA; Pretorius, M; Sprinkel, KC, 2015) |
| " The diet was randomly supplemented with keto-amino acids at a dosage of 100 mg/kg BW per day (66 patients, Group I); 65 patients received placebo (Group II)." | 2.73 | Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial. ( Hanzal, V; Malý, J; Mareckova, O; Racek, J; Schück, O; Stollova, M; Teplan, V, 2008) |
| "Twenty ESRD patients (11 women) were studied during both a single online HDF session and a single HD session." | 2.72 | No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. ( Bode-Boger, SM; Dusilová-Sulková, S; Hodková, M; Kalousová, M; Kielstein, JT; Martens-Lobenhoffer, J; Zima, T, 2006) |
| "Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors." | 2.72 | Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. ( Aslam, S; Leone, A; Santha, T; Wilcox, C, 2006) |
| "Thus, subjects with chronic renal failure are exposed to increased morbidity and mortality from cardiovascular events." | 2.44 | Cardiac biomarkers and chronic renal diseases. ( Kristofova, B; Valocik, G; Valocikova, I, 2008) |
| "In patients with cardiac diseases, c(SDMA) was additionally increased only in the CRF group." | 2.42 | Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. ( Busch, M; Fleck, C; Karge, E; Schweitzer, F; Stein, G, 2003) |
| "Seventy-five patients (M/F = 40/35) with chronic renal failure (CRF) and who were on HD were divided into five groups with differing treatment periods of HD; from 6 to 24 months to 97-120 months." | 1.40 | Changes in serum asymmetric dimethylarginine and endothelial markers levels with varying periods of hemodialysis. ( Demir, S; Karabag, F; Koken, T; Yaman, A, 2014) |
| "53 patients with chronic renal failure receiving hemodialysis treatment and 34 healthy persons were participated to the study." | 1.40 | Levels of arginine and its products in dialysis patients. ( Akyurek, F; Erdem, SS; Kiyici, A; Ozturk, B; Sivrikaya, A; Ugurcu, V; Unlu, A; Vatansev, H, 2014) |
| "Ezetimibe treatment (10mg/day) for 6 months significantly decreased circulating levels of LDL-cholesterol, triglycerides and ADMA, while it increased HDL-cholesterol levels." | 1.35 | Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. ( Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2009) |
| "Elevated plasma ADMA was confirmed in ESRD and HTN populations while basal WBSUP ADMA was significantly higher in ESRD subjects than controls (P = 0." | 1.35 | Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. ( Billecke, SS; D'Alecy, LG; Gadegbeku, CA; Jamerson, KA; Perlman, RL; Platel, R; Whitesall, SE, 2009) |
| "In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions." | 1.35 | Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. ( Bode-Boger, SM; Csiky, B; Lakatos, O; Martens-Lobenhoffer, J; Sulyok, E; Wittmann, I, 2008) |
| "Vascular dysfunction in chronic renal failure may be linked to reduced nitric oxide (NO) bioactivity and increased circulating concentrations of the endogenous NO synthase inhibitor asymmetrical dimethyl L-arginine (ADMA)." | 1.33 | Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. ( Hörl, WH; Mittermayer, F; Pleiner, J; Schaller, G; Sunder-Plassmann, G; Vychytil, A; Wolzt, M, 2005) |
| "Reduced bioavailability of nitric oxide (NO) is thought to play an important role in progression of renal damage." | 1.33 | Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. ( Bode-Böger, SM; Fliser, D; Haller, H; Kielstein, JT; Kronenberg, F; Morath, C; Ritz, E, 2005) |
| "Because UTN accumulates in patients with chronic renal failure, the association between plasma UTN and biomarkers of atherosclerosis and endothelial activation needs to be better understood." | 1.33 | Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. ( Cutrupi, S; Mallamaci, F; Pizzini, P; Tripepi, G; Zoccali, C, 2006) |
| "The corresponding values for end-stage chronic renal failure patients are ARG = 48." | 1.32 | Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. ( Bode-Böger, SM; Krug, O; Martens-Lobenhoffer, J, 2004) |
| "In end-stage renal disease (ESRD), Framingham risk factors do not fully explain the cardiovascular burden of these patients." | 1.31 | Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. ( Zoccali, C, 2002) |
| "However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis." | 1.28 | Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. ( Calver, A; Collier, J; Leone, A; Moncada, S; Vallance, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.03) | 18.2507 |
| 2000's | 84 (67.74) | 29.6817 |
| 2010's | 33 (26.61) | 24.3611 |
| 2020's | 2 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, CC | 1 |
| Hsieh, MY | 1 |
| Lee, CK | 1 |
| Chuang, SY | 1 |
| Chung, MY | 1 |
| Lin, CC | 1 |
| Du, Q | 1 |
| Gao, J | 1 |
| Lu, R | 1 |
| Jin, Y | 1 |
| Zou, Y | 1 |
| Yu, C | 1 |
| Yan, Y | 1 |
| Bentli, R | 1 |
| Taskapan, H | 1 |
| Taskapan, MC | 1 |
| Dogan, A | 1 |
| Alshahawey, M | 1 |
| Shahin, SM | 1 |
| Elsaid, TW | 1 |
| Sabri, NA | 1 |
| Torino, C | 1 |
| Pizzini, P | 3 |
| Cutrupi, S | 4 |
| Tripepi, R | 1 |
| Tripepi, G | 14 |
| Mallamaci, F | 14 |
| Zoccali, C | 23 |
| Małgorzewicz, S | 1 |
| Heleniak, Z | 1 |
| Lichodziejewska-Niemierko, M | 1 |
| Rutkowski, R | 1 |
| Aleksandrowicz-Wrona, E | 1 |
| Dębska-Ślizień, A | 1 |
| Ignjatović, AM | 1 |
| Cvetković, TP | 1 |
| Pavlović, RM | 1 |
| Đorđević, VM | 1 |
| Milošević, ZG | 1 |
| Đorđević, VB | 1 |
| Pavlović, DD | 1 |
| Stojanović, IR | 1 |
| Bogdanović, D | 1 |
| Avci, E | 1 |
| Cakir, E | 2 |
| Cevher, SC | 1 |
| Yaman, H | 1 |
| Agilli, M | 1 |
| Bilgi, C | 1 |
| Hammes, MS | 1 |
| Watson, S | 1 |
| Coe, FL | 1 |
| Ahmed, F | 1 |
| Beltran, E | 1 |
| Dhar, P | 1 |
| Drew, DA | 1 |
| Tighiouart, H | 1 |
| Scott, T | 1 |
| Kantor, A | 1 |
| Fan, L | 1 |
| Artusi, C | 1 |
| Plebani, M | 1 |
| Weiner, DE | 1 |
| Sarnak, MJ | 1 |
| Yaman, A | 1 |
| Karabag, F | 1 |
| Demir, S | 1 |
| Koken, T | 1 |
| Ugurcu, V | 1 |
| Vatansev, H | 1 |
| Unlu, A | 1 |
| Sivrikaya, A | 1 |
| Akyurek, F | 1 |
| Ozturk, B | 1 |
| Kiyici, A | 1 |
| Erdem, SS | 1 |
| Cifci, A | 1 |
| Inal, S | 1 |
| Kaya, C | 1 |
| El Shahawy, Y | 1 |
| Soliman, Y | 1 |
| Rifaie, A | 1 |
| Shenawy, H | 1 |
| Behairy, M | 1 |
| Mady, G | 1 |
| Aldámiz-Echevarria, L | 1 |
| Andrade, F | 1 |
| Llarena, M | 1 |
| de Las Heras, J | 1 |
| Couce, ML | 1 |
| Gamboa, JL | 1 |
| Pretorius, M | 1 |
| Sprinkel, KC | 1 |
| Brown, NJ | 1 |
| Ikizler, TA | 1 |
| Kanbay, M | 1 |
| Afsar, B | 1 |
| Siriopol, D | 1 |
| Unal, HU | 1 |
| Karaman, M | 1 |
| Saglam, M | 2 |
| Eyileten, T | 2 |
| Gezer, M | 1 |
| Verim, S | 1 |
| Oguz, Y | 2 |
| Vural, A | 2 |
| Ortiz, A | 1 |
| Johnson, RJ | 1 |
| Covic, A | 1 |
| Yilmaz, MI | 2 |
| Parrish, AR | 1 |
| Naito, T | 1 |
| Sanaka, T | 1 |
| Mikami, H | 1 |
| Soga, A | 1 |
| Yamatani, K | 1 |
| Segawa, K | 1 |
| Kawashima, M | 1 |
| Yoshikura, T | 1 |
| Niwayama, J | 1 |
| Nishimura, H | 1 |
| Ogawa, T | 1 |
| Ando, A | 1 |
| Teramoto, A | 1 |
| Nitta, K | 1 |
| El-Mesallamy, HO | 1 |
| Abdel Hamid, SG | 1 |
| Gad, MZ | 1 |
| Mangoni, AA | 1 |
| Hewitson, CL | 1 |
| Woodman, RJ | 1 |
| Whiting, MJ | 1 |
| McAteer-Carr, B | 1 |
| Barbara, JA | 1 |
| Ebinç, FA | 1 |
| Erten, Y | 1 |
| Ebinç, H | 1 |
| Paşaoğlu, H | 1 |
| Demirtaş, C | 1 |
| Taçoy, G | 1 |
| Mutluay, R | 1 |
| Koç, E | 1 |
| Derici, U | 1 |
| Reis, KA | 1 |
| Bali, M | 1 |
| Arinsoy, T | 1 |
| Sindel, S | 1 |
| Calò, LA | 1 |
| Davis, PA | 1 |
| Ueda, S | 5 |
| Matsumoto, Y | 3 |
| Kaida, Y | 2 |
| Okuda, S | 5 |
| Yamagishi, S | 5 |
| Billecke, SS | 1 |
| D'Alecy, LG | 1 |
| Platel, R | 1 |
| Whitesall, SE | 1 |
| Jamerson, KA | 1 |
| Perlman, RL | 1 |
| Gadegbeku, CA | 1 |
| Teplan, V | 2 |
| Schück, O | 1 |
| Racek, J | 2 |
| Mareckova, O | 1 |
| Stollova, M | 1 |
| Hanzal, V | 1 |
| Malý, J | 1 |
| Valocikova, I | 1 |
| Kristofova, B | 1 |
| Valocik, G | 1 |
| Kocak, H | 2 |
| Gumuslu, S | 2 |
| Sahin, E | 2 |
| Ceken, K | 1 |
| Gocmen, YA | 1 |
| Yakupoglu, G | 2 |
| Ersoy, FF | 1 |
| Tuncer, M | 2 |
| Fujimi-Hayashida, A | 1 |
| Koike, K | 1 |
| Tanaka, H | 1 |
| Fukami, K | 2 |
| Zhang, DL | 2 |
| Liao, H | 1 |
| Wei, YY | 1 |
| Zhang, Y | 2 |
| Zhang, QD | 1 |
| Wang, ZG | 1 |
| Nakamura, T | 3 |
| Sato, E | 4 |
| Fujiwara, N | 4 |
| Kawagoe, Y | 3 |
| Ueda, Y | 3 |
| Suzuki, T | 2 |
| Adachi, H | 2 |
| Aucella, F | 1 |
| Maas, R | 7 |
| Vigilante, M | 1 |
| Schwedhelm, E | 1 |
| Margaglione, M | 1 |
| Gesualdo, L | 1 |
| Boeger, R | 2 |
| Yamada, S | 1 |
| Takeuchi, M | 1 |
| Matsui, T | 1 |
| Caplin, B | 1 |
| Nitsch, D | 1 |
| Gill, H | 1 |
| Hoefield, R | 1 |
| Blackwell, S | 1 |
| MacKenzie, D | 1 |
| Cooper, JA | 1 |
| Middleton, RJ | 1 |
| Talmud, PJ | 1 |
| Veitch, P | 1 |
| Norman, J | 1 |
| Wheeler, DC | 1 |
| Leiper, JM | 1 |
| Koyama, K | 1 |
| Ito, A | 1 |
| Yamamoto, J | 1 |
| Nishio, T | 1 |
| Kajikuri, J | 1 |
| Dohi, Y | 1 |
| Ohte, N | 1 |
| Sano, A | 1 |
| Nakamura, H | 1 |
| Kumagai, H | 2 |
| Itoh, T | 1 |
| Liu, J | 1 |
| Liu, S | 1 |
| Liu, WH | 1 |
| Lee, KH | 1 |
| Gil, HW | 1 |
| Yang, JO | 1 |
| Lee, EY | 1 |
| Hong, SY | 1 |
| Hov, GG | 1 |
| Sagen, E | 1 |
| Hatlen, G | 1 |
| Bigonah, A | 1 |
| Åsberg, A | 1 |
| Aasarød, K | 1 |
| Moriguchi, Y | 1 |
| Yogo, K | 1 |
| Aizawa, K | 1 |
| Serizawa, K | 1 |
| Tashiro, Y | 1 |
| Yorozu, K | 1 |
| Ishizuka, N | 1 |
| Iwabuchi, S | 1 |
| Kitamura, H | 1 |
| Nishimura, T | 1 |
| Sladen, RN | 1 |
| Mattace Raso, F | 1 |
| Sijbrands, E | 1 |
| Seck, MS | 1 |
| Boger, R | 5 |
| Witteman, J | 1 |
| Rapisarda, F | 1 |
| Malatino, L | 4 |
| Bugnicourt, JM | 1 |
| Da Silveira, C | 1 |
| Bengrine, A | 1 |
| Godefroy, O | 1 |
| Baumbach, G | 1 |
| Sevestre, H | 1 |
| Bode-Boeger, SM | 1 |
| Kielstein, JT | 10 |
| Massy, ZA | 1 |
| Chillon, JM | 1 |
| Hikichi, Y | 1 |
| Node, K | 1 |
| Suntharalingam, M | 1 |
| Perthel, R | 1 |
| Rong, S | 1 |
| Martens-Lobenhoffer, J | 5 |
| Jäger, K | 1 |
| Bode-Böger, SM | 9 |
| Nave, H | 1 |
| Chen, GF | 1 |
| Moningka, NC | 1 |
| Sasser, JM | 1 |
| Zharikov, S | 1 |
| Cunningham, M | 1 |
| Tain, YL | 1 |
| Schwartz, IF | 1 |
| Baylis, C | 4 |
| Alsagaff, MY | 1 |
| Thaha, M | 1 |
| Aminuddin, M | 1 |
| Yogiarto, RM | 1 |
| Yogiantoro, M | 1 |
| Tomino, Y | 1 |
| Napora, M | 1 |
| Graczykowska, A | 1 |
| Próchniewska, K | 1 |
| Zdrojewski, Z | 1 |
| Całka, A | 1 |
| Górny, J | 1 |
| Stompór, T | 1 |
| Hojs, R | 1 |
| Bevc, S | 1 |
| Ekart, R | 1 |
| Li, H | 1 |
| Wang, S | 2 |
| Wagner, L | 2 |
| Riggleman, A | 1 |
| Erdely, A | 1 |
| Couser, W | 1 |
| Osanai, T | 2 |
| Saitoh, M | 2 |
| Sasaki, S | 2 |
| Tomita, H | 2 |
| Nakamura, M | 2 |
| Osawa, H | 2 |
| Yamabe, H | 2 |
| Okumura, K | 2 |
| Chan, NN | 1 |
| Chan, WB | 1 |
| Chan, JC | 1 |
| Zhang, WR | 2 |
| Tao, LJ | 2 |
| Chen, BM | 2 |
| Hörl, WH | 3 |
| Fleck, C | 2 |
| Schweitzer, F | 2 |
| Karge, E | 2 |
| Busch, M | 1 |
| Stein, G | 2 |
| Tsikas, D | 1 |
| Rode, I | 1 |
| Becker, T | 1 |
| Nashan, B | 1 |
| Klempnauer, J | 1 |
| Frölich, JC | 4 |
| Murakami, S | 1 |
| Magota, K | 1 |
| Böger, RH | 5 |
| Ritz, E | 4 |
| Smirnova, IV | 1 |
| Sawamura, T | 1 |
| Goligorsky, MS | 1 |
| Cohen, JJ | 1 |
| Harrington, JT | 1 |
| Madias, NE | 1 |
| Zusman, CJ | 1 |
| Krug, O | 1 |
| Mittermayer, F | 1 |
| Schaller, G | 1 |
| Pleiner, J | 1 |
| Vychytil, A | 1 |
| Sunder-Plassmann, G | 1 |
| Wolzt, M | 1 |
| Malatino, LS | 2 |
| Fliser, D | 3 |
| Kronenberg, F | 1 |
| Morath, C | 1 |
| Haller, H | 3 |
| Ravani, P | 1 |
| Malberti, F | 1 |
| Testa, S | 1 |
| Enia, G | 1 |
| Panuccio, V | 1 |
| Testa, A | 2 |
| Spoto, B | 2 |
| Fatuzzo, P | 1 |
| Nanayakkara, PW | 1 |
| Teerlink, T | 2 |
| Stehouwer, CD | 1 |
| Allajar, D | 1 |
| Spijkerman, A | 1 |
| Schalkwijk, C | 1 |
| ter Wee, PM | 1 |
| van Guldener, C | 1 |
| Morimoto, H | 2 |
| Nakao, K | 2 |
| Fukuoka, K | 1 |
| Sarai, A | 2 |
| Yano, A | 2 |
| Kihara, T | 2 |
| Fukuda, S | 1 |
| Wada, J | 1 |
| Makino, H | 2 |
| Westphal, S | 1 |
| Awiszus, F | 1 |
| Luley, C | 1 |
| Chan, CT | 1 |
| Harvey, PJ | 1 |
| Pierratos, A | 1 |
| Floras, JS | 1 |
| Akagi, S | 1 |
| Nakamura, A | 1 |
| Hiramatsu, M | 1 |
| Nagake, Y | 1 |
| Benedetto, FA | 4 |
| Boeger, RH | 1 |
| Parlongo, RM | 1 |
| Pisano, A | 1 |
| Siroká, R | 1 |
| Cibulka, R | 1 |
| Rajdl, D | 1 |
| Matsuguma, K | 1 |
| Kaneyuki, U | 1 |
| Shibata, R | 1 |
| Fujimura, T | 1 |
| Matsuoka, H | 1 |
| Kimoto, M | 1 |
| Kato, S | 1 |
| Imaizumi, T | 1 |
| Bellinghieri, G | 1 |
| Santoro, D | 1 |
| Mallamace, A | 1 |
| Di Giorgio, RM | 1 |
| De Luca, G | 1 |
| Savica, V | 1 |
| Cooke, JP | 1 |
| Kalousová, M | 1 |
| Hodková, M | 1 |
| Zima, T | 1 |
| Dusilová-Sulková, S | 1 |
| Sakurai, M | 1 |
| Takita, T | 1 |
| Maruyama, Y | 1 |
| Uno, S | 1 |
| Ikegaya, N | 1 |
| Kato, A | 1 |
| Hishida, A | 1 |
| Hou, FF | 1 |
| Ning, JP | 1 |
| Yang, XB | 1 |
| Wu, Q | 1 |
| Li, HY | 1 |
| Chang, L | 1 |
| Aslam, S | 1 |
| Santha, T | 1 |
| Leone, A | 2 |
| Wilcox, C | 1 |
| Chang, JW | 1 |
| Lee, EK | 1 |
| Kim, TH | 1 |
| Min, WK | 1 |
| Chun, S | 1 |
| Lee, KU | 1 |
| Kim, SB | 1 |
| Park, JS | 1 |
| Yamamizu, K | 1 |
| Shinozaki, K | 1 |
| Ayajiki, K | 1 |
| Gemba, M | 1 |
| Okamura, T | 1 |
| Soveri, I | 1 |
| Lind, L | 1 |
| Wikstrom, B | 1 |
| Zilmer, M | 1 |
| Zilmer, K | 1 |
| Fellström, B | 1 |
| Grooteman, MP | 1 |
| Wauters, IM | 1 |
| Twisk, JW | 1 |
| Nubé, MJ | 1 |
| Vicente, FB | 1 |
| Miller, A | 1 |
| Brooks, ER | 1 |
| Price, HE | 1 |
| Smith, FA | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Kurt, Y | 1 |
| Tasar, M | 1 |
| Acikel, C | 1 |
| Yenicesu, M | 1 |
| Ermis, C | 1 |
| Mahsereci, E | 1 |
| Gocmen, AY | 1 |
| Ersoy, F | 1 |
| Suleymanlar, G | 1 |
| Desai, A | 1 |
| Zhao, Y | 1 |
| Warren, JS | 1 |
| Csiky, B | 1 |
| Sulyok, E | 1 |
| Lakatos, O | 1 |
| Wittmann, I | 1 |
| Uzun, H | 1 |
| Konukoglu, D | 1 |
| Besler, M | 1 |
| Erdenen, F | 1 |
| Sezgin, C | 1 |
| Muderrisoglu, C | 1 |
| Mendes Ribeiro, AC | 1 |
| Roberts, NB | 1 |
| Lane, C | 1 |
| Yaqoob, M | 1 |
| Ellory, JC | 1 |
| MacAllister, RJ | 1 |
| Rambausek, MH | 1 |
| Vallance, P | 2 |
| Williams, D | 1 |
| Hoffmann, KH | 1 |
| Kang, ES | 2 |
| Tevlin, MT | 2 |
| Wang, YB | 1 |
| Chiang, TM | 1 |
| Cardenas, R | 1 |
| Myers, LK | 1 |
| Acchiardo, SR | 2 |
| Schäffer, J | 1 |
| Barbey, M | 1 |
| Koch, KM | 1 |
| Caussé, E | 1 |
| Siri, N | 1 |
| Arnal, JF | 1 |
| Bayle, C | 1 |
| Malatray, P | 1 |
| Valdiguié, P | 1 |
| Salvayre, R | 1 |
| Couderc, F | 1 |
| Janz, A | 1 |
| Schwertfeger, M | 1 |
| Schröder, M | 1 |
| Riedel, E | 1 |
| Beck, W | 1 |
| Deppisch, RM | 1 |
| Pommer, W | 1 |
| Miles, DE | 1 |
| Cates, TB | 1 |
| Xiao, S | 1 |
| Schmidt, RJ | 1 |
| Wahbi, N | 1 |
| Dalton, RN | 1 |
| Turner, C | 1 |
| Denton, M | 1 |
| Abbs, I | 1 |
| Swaminathan, R | 1 |
| Xiao, ZS | 1 |
| Quarles, LD | 1 |
| Chen, QQ | 1 |
| Yu, YH | 1 |
| Qu, XP | 1 |
| Jiang, CH | 1 |
| Deng, HW | 1 |
| Li, YJ | 1 |
| Zhou, HH | 1 |
| Salvatore Malatino, L | 1 |
| Raj, DS | 1 |
| Vincent, B | 1 |
| Simpson, K | 1 |
| Jones, KL | 1 |
| Welbourne, TC | 1 |
| Levi, M | 1 |
| Shah, V | 1 |
| Blandon, P | 1 |
| Zager, P | 1 |
| Robbins, RA | 1 |
| Cataliotti, A | 1 |
| Bellanuova, I | 1 |
| Calver, A | 1 |
| Collier, J | 1 |
| Moncada, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2[NCT00732069] | Phase 2 | 19 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The RAS, Fibrinolysis and Cardiopulmonary Bypass[NCT00607672] | Phase 4 | 111 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study[NCT01255969] | Phase 4 | 500 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease[NCT00384618] | Phase 4 | 100 participants | Interventional | 2001-05-31 | Terminated | ||
| Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234] | Phase 4 | 32 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean difference in F2-isoprostanes during dialysis between treatment with ramipril or valsartan and placebo (NCT00732069)
Timeframe: During dialysis after one week of study drug
| Intervention | pg/mL (Mean) |
|---|---|
| Ramipril | 59.55 |
| Valsartan | 59.03 |
| Placebo | 50.23 |
Mean difference in interleukin 1 beta concentration during treatment with ramipril versus treatment with placebo (NCT00732069)
Timeframe: During dialysis after one week of study drug
| Intervention | pg/mL (Mean) |
|---|---|
| Ramipril | 6.18 |
| Valsartan | 2.16 |
| Placebo | 1.44 |
Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery. (NCT00607672)
Timeframe: From the start of surgery until postoperative day 3
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 28.6 |
| Ramipril (ACEI) | 23.8 |
| Candesartan (ARB) | 36.4 |
Blood loss over 24 hours as measured by chest tube output (NCT00607672)
Timeframe: First 24 hours after arrival in the intensive care unit
| Intervention | mL (Mean) |
|---|---|
| Placebo | 437 |
| Ramipril (ACEI) | 470 |
| Candesartan (ARB) | 511 |
(NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | days (Mean) |
|---|---|
| Placebo | 7.7 |
| Ramipril (ACEI) | 6.3 |
| Candesartan (ARB) | 8.1 |
New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 17.9 |
| Ramipril (ACEI) | 16.7 |
| Candesartan (ARB) | 27.3 |
The percentage of patients that were taken back to the operating room for re-exploration because of bleeding (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 3.6 |
| Ramipril (ACEI) | 8.3 |
| Candesartan (ARB) | 4.5 |
New onset neurological deficit with a duration of longer than 24 hours (NCT00607672)
Timeframe: From arrival in intensive care unit until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 7.1 |
| Ramipril (ACEI) | 4.2 |
| Candesartan (ARB) | 4.5 |
Percentage of patients that received blood product transfusion (NCT00607672)
Timeframe: From the start of surgery until discharge from hospital
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Packed red blood cells | Plasma | Platelets | Cryoprecipitate | |
| Candesartan (ARB) | 2.7 | 31.8 | 22.7 | 4.5 |
| Placebo | 67.9 | 60.7 | 46.4 | 7.1 |
| Ramipril (ACEI) | 62.5 | 29.2 | 29.2 | 4.2 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 4.21 | 749.56 | 22.55 | 14.26 |
| Placebo | 4.45 | 461.90 | 30.70 | 16.74 |
| Ramipril (ACEI) | 5.36 | 815.74 | 26.89 | 14.59 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 6.44 | 144.76 | 218.16 | 243.72 |
| Placebo | 6.29 | 116.04 | 224.96 | 166.96 |
| Ramipril (ACEI) | 9.33 | 167.51 | 172.65 | 144.67 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8 (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Pre CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 13.38 | 76.76 | 37.11 | 37.77 |
| Placebo | 16.18 | 66.44 | 46.18 | 34.39 |
| Ramipril (ACEI) | 11.86 | 80.07 | 37.39 | 28.06 |
To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 18.28 | 24.19 | 49.10 | 21.70 | 13.4 |
| Placebo | 15.14 | 20.43 | 39.69 | 31.83 | 21.59 |
| Ramipril (ACEI) | 16.25 | 19.41 | 41.62 | 26.27 | 17.33 |
To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response (NCT00607672)
Timeframe: From the start of surgery until postoperative day 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| Pre CPB | 60min of CPB | Post surgery | Postoperative day 1 | Postoperative day 2 | |
| Candesartan (ARB) | 11.97 | 24.89 | 31.47 | 15.75 | 12.89 |
| Placebo | 14.36 | 27.65 | 34.56 | 20.25 | 16.56 |
| Ramipril (ACEI) | 14.05 | 36.67 | 41.11 | 17.10 | 12.49 |
(NCT00607672)
Timeframe: From the end of cardiopulmonary bypass until arrival in intensive care unit
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| Dobutamine | Mlrinone | Norepinephrine | Epinephrine | |
| Candesartan (ARB) | 27.3 | 22.7 | 95.5 | 13.6 |
| Placebo | 35.7 | 25.0 | 85.7 | 7.1 |
| Ramipril (ACEI) | 29.2 | 25.0 | 79.2 | 4.3 |
Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -0.66 |
| Metoprolol | -2.35 |
The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 2.16 |
| Metoprolol | 10.43 |
"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -1.07 |
| Metoprolol | -3.19 |
Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | -8.14 |
| Metoprolol | 8.70 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol < 50 Years Old | 51.55 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: Baseline and Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol <50 Year Old | 51.55 |
| Metoprolol >/= 50 Year Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol >/=50 Years Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: 12 Months
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Nebivolol | 50.07 |
| Metoprolol | 38.13 |
Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 11.47 |
| Metoprolol | -17.27 |
Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -2.65 |
| Metoprolol | -3.88 |
19 reviews available for n(g),n(g')-dimethyl-l-arginine and Kidney Failure, Chronic
| Article | Year |
|---|---|
The cytoskeleton as a novel target for treatment of renal fibrosis.
Topics: Actins; Animals; Arginine; Cytoskeleton; Disease Progression; Epithelial Cells; Fibrosis; Humans; Ki | 2016 |
[Endothelial injury and CKD].
Topics: Animals; Arginine; Cardiovascular Diseases; Chronic Disease; Endothelium, Vascular; Humans; Kidney D | 2008 |
Cardiac biomarkers and chronic renal diseases.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Disease Progression; Hom | 2008 |
Biomarkers in hemodialysis patients.
Topics: Animals; Arginine; Biomarkers; Cardiovascular Physiological Phenomena; Cell Adhesion Molecules; Huma | 2012 |
[Cardiovascular events in chronic advanced renal insufficiency. Current concepts].
Topics: Anemia; Arginine; C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperhomocysteinemia; Hyperli | 2003 |
[Atherosclerosis and uremia: signifance of non-traditional risk factors].
Topics: Arginine; Arteriosclerosis; Homocysteine; Humans; Kidney Failure, Chronic; Oxidative Stress; Phospha | 2003 |
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.
Topics: Amino Acids; Arginine; Case-Control Studies; Creatinine; Heart Diseases; Humans; Hypertension; Kidne | 2003 |
ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Topics: Arginine; Cardiovascular Diseases; Endothelium, Vascular; Enzyme Inhibitors; Humans; Kidney Failure, | 2003 |
Novel cardiovascular risk factors in end-stage renal disease.
Topics: Arginine; Calcinosis; Cardiovascular Diseases; Humans; Hypertension; Inflammation; Kidney Failure, C | 2004 |
Atherosclerosis in dialyzed patients.
Topics: Anemia; Animals; Arginine; Arteriosclerosis; Biomarkers; Cause of Death; Comorbidity; Coronary Arter | 2004 |
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
Topics: Adult; Aged; Aged, 80 and over; Animals; Arginine; Arteriosclerosis; Biomarkers; Cardiovascular Dise | 2004 |
Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients.
Topics: Arginine; Autonomic Nervous System Diseases; C-Reactive Protein; Cardiovascular Diseases; Humans; Hy | 2005 |
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Carotid Arteries; Carotid S | 2005 |
Biomarkers in chronic kidney disease: utility and issues towards better understanding.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Chronic Disease; Disease Progression; Glomerular | 2005 |
[Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Endothelium, Vascular; Humans; Kid | 2006 |
L-arginine: a new opportunity in the management of clinical derangements in dialysis patients.
Topics: Adult; Aged; Animals; Arginine; Citrulline; Diabetic Nephropathies; Endothelium, Vascular; Female; H | 2006 |
Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Topics: Absorption; Amidohydrolases; Arginine; Biological Availability; Cardiovascular Diseases; Chronic Dis | 2006 |
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; | 2006 |
Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
Topics: Arginine; Arteriosclerosis; Biomarkers; Humans; In Vitro Techniques; Kidney Failure, Chronic; Nitric | 2001 |
21 trials available for n(g),n(g')-dimethyl-l-arginine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Arginine; Aspartate Aminotransferases; C-Reactive | 2017 |
Vitamin D and methylarginines in chronic kidney disease (CKD).
Topics: Aged; Arginine; Calcium; Cross-Sectional Studies; Double-Blind Method; Ergocalciferols; Female; Huma | 2017 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradyki | 2015 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradyki | 2015 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradyki | 2015 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradyki | 2015 |
Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial.
Topics: Adult; Aged; Amino Acids; Arginine; Combined Modality Therapy; Diet, Protein-Restricted; Dietary Sup | 2008 |
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
Topics: Administration, Oral; Aged; Arginine; Cardiovascular Diseases; Drug Therapy, Combination; Female; Fo | 2010 |
The differences of asymmetric dimethylarginine removal by different dialysis treatments.
Topics: Adult; Age Factors; Aged; Arginine; Dialysis Solutions; Female; Glomerular Filtration Rate; Humans; | 2010 |
Renovascular protective effects of erythropoietin in patients with chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acute Kidney Injury; Aged; Arginine; Atherosclerosis; Biomarkers; Cardi | 2011 |
Organic nitrates favor regression of left ventricular hypertrophy in hypertensive patients on chronic peritoneal dialysis.
Topics: Adult; Aged; Antihypertensive Agents; Arginine; Blood Pressure; Female; Humans; Hypertension; Hypert | 2013 |
Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease.
Topics: Arginine; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Failure, Chr | 2002 |
Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
Topics: Adult; Aged; Antioxidants; Arginine; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Female | 2005 |
Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arginine; Biomarkers; Coated Materials, Biocompatible; | 2005 |
Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA.
Topics: Adult; Appointments and Schedules; Arginine; Circadian Rhythm; Endothelium, Vascular; Female; Humans | 2005 |
No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients.
Topics: Adult; Aged; Arginine; beta 2-Microglobulin; Female; Hemodiafiltration; Humans; Kidney Failure, Chro | 2006 |
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood | 2006 |
Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
Topics: Adult; Antioxidants; Arginine; Biomarkers; C-Reactive Protein; Cholesterol; Chromatography, High Pre | 2007 |
Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels.
Topics: Aged; Arginine; Blood Pressure; Female; Humans; Kidney Failure, Chronic; Male; Renal Dialysis | 2007 |
Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied.
Topics: Adult; Aged; Aged, 80 and over; Arginine; beta 2-Microglobulin; Biocompatible Materials; Complement | 2007 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; | 2007 |
The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.
Topics: Adult; Arginine; Atherosclerosis; C-Reactive Protein; Endothelium, Vascular; Female; Humans; Inflamm | 2008 |
Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.
Topics: Adult; Aged; Arginine; Chromatography, High Pressure Liquid; Female; Humans; Kidney Failure, Chronic | 1996 |
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
Topics: Adult; Aged; Analysis of Variance; Arginine; Arteriosclerosis; Female; Humans; Kidney Failure, Chron | 1999 |
84 other studies available for n(g),n(g')-dimethyl-l-arginine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Dimethylarginine Dimethylaminohydrolase 1 Polymorphisms and Venous Intimal Hyperplasia in Hemodialysis Patients.
Topics: Aged; Aged, 80 and over; Amidohydrolases; Arginine; Arteriovenous Shunt, Surgical; Female; Follow-Up | 2019 |
Asymmetric dimethylarginine compartmental behavior during high-flux hemodialysis.
Topics: Adult; Arginine; Cardiovascular Diseases; Creatinine; Humans; Kidney Failure, Chronic; Male; Middle | 2020 |
Serum asymmetric-dimethylarginine, apelin and NT-pro BNP levels in dialysis patients.
Topics: Adult; Aged; Apelin; Arginine; Biomarkers; Blood Pressure; Blood Pressure Determination; Female; Hum | 2020 |
Protein-energy wasting and asymmetric dimethylarginine in peritoneal dialysis patients.
Topics: Adiponectin; Adult; Aged; Arginine; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Ca | 2018 |
Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Fem | 2013 |
Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; D | 2014 |
Asymmetric dimethylarginine and whole blood viscosity in renal failure.
Topics: Adult; Arginine; Blood Viscosity; Female; Humans; Kidney Failure, Chronic; Male; Risk Factors; Young | 2015 |
Asymmetric dimethylarginine, race, and mortality in hemodialysis patients.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Black or African American; Boston; Cause of Death; Fe | 2014 |
Changes in serum asymmetric dimethylarginine and endothelial markers levels with varying periods of hemodialysis.
Topics: Adult; Aged; Arginine; Case-Control Studies; Female; Humans; Intercellular Adhesion Molecule-1; Kidn | 2014 |
Levels of arginine and its products in dialysis patients.
Topics: Adult; Aged; Arginine; Coronary Artery Disease; Female; Humans; Kidney Failure, Chronic; Male; Middl | 2014 |
Asymmetric dimethyl arginine levels in chronic hemodialysis patients.
Topics: Adult; Aged; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Cross-Sect | 2014 |
Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
Topics: Adult; Arginine; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventric | 2015 |
Dimethylarginines as biomarkers for the kidney transplant management in methylmalonic aciduria.
Topics: Adult; Allografts; Amino Acid Metabolism, Inborn Errors; Arginine; Biomarkers; Cause of Death; Disea | 2015 |
Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
Topics: Academic Medical Centers; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohor | 2016 |
Modulation of circulating endothelial progenitor cells by erythropoiesis-stimulating agents in patients with chronic kidney disease stage G5 and 5D
.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Cell Count; Darbepoetin alfa; Endothelial Progenito | 2016 |
Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake.
Topics: Aged; Arginine; Cardiovascular Diseases; Case-Control Studies; Homocysteine; Humans; Kidney Failure, | 2008 |
Symmetric dimethylarginine is an independent predictor of intradialytic hypotension.
Topics: Aged; Arginine; Biomarkers; Blood Pressure; Female; Humans; Hypotension; Kidney Failure, Chronic; Ma | 2008 |
The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Case-Control Studies; Creatinine; Female; Follow- | 2008 |
EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1.
Topics: Animals; Apoptosis; Arginine; Endothelium, Vascular; Epoetin Alfa; Erythropoietin; Heme Oxygenase-1; | 2008 |
Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Erythrocytes; Female; Humans; Hypertension; Kidne | 2009 |
Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients.
Topics: Adult; Arginine; Cross-Sectional Studies; Endothelium, Vascular; Female; Glycation End Products, Adv | 2009 |
Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
Topics: Arginine; Cardiovascular Diseases; Carotid Arteries; Humans; Kidney Diseases; Kidney Failure, Chroni | 2009 |
Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
Topics: Amidohydrolases; Animals; Arginine; Capillaries; Disease Models, Animal; Glomerulosclerosis, Focal S | 2009 |
Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Female; Humans; Intercellular Signaling Peptid | 2009 |
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Topics: Adult; Arginine; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Humans; Kidney Failure, | 2009 |
Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
Topics: Adult; Aged; Arginine; Biomarkers; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failur | 2009 |
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Topics: Adult; Arginine; Cross-Sectional Studies; Dyslipidemias; Female; Glycation End Products, Advanced; H | 2009 |
Effect of keto acids on asymmetric dimethylarginine, muscle, and fat tissue in chronic kidney disease and after kidney transplantation.
Topics: Adipose Tissue; Adult; Aged; Amino Acids; Arginine; Body Mass Index; Diet, Protein-Restricted; Human | 2009 |
Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.
Topics: Alleles; Amidohydrolases; Arginine; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; E | 2010 |
Sequential change of asymmetric dimethylarginine levels after initiation of peritoneal dialysis in patients with end-stage renal disease.
Topics: Aged; Arginine; Biomarkers; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nutritional | 2010 |
Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Cardiovascular Diseases; Female; Glomerular Fi | 2011 |
Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats.
Topics: Animals; Arginine; Creatinine; Disease Models, Animal; Fibrosis; Hypertension; Hypertrophy, Left Ven | 2011 |
Chronic kidney disease: the silent enemy?
Topics: Anesthesiology; Arginine; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Ch | 2011 |
Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
Topics: Adult; Aged; Analysis of Variance; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases | 2011 |
Chronic renal failure alters endothelial function in cerebral circulation in mice.
Topics: Analysis of Variance; Animals; Apolipoproteins E; Arginine; Arterioles; Blotting, Western; Caveolin | 2011 |
Asymmetric dimethylarginine may mediate increased heat pain threshold in experimental chronic kidney disease.
Topics: Animals; Arginine; Enzyme Inhibitors; Hot Temperature; Kidney Failure, Chronic; Male; Nephrectomy; N | 2012 |
Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat.
Topics: Animals; Aorta; Arginase; Arginine; Creatinine; Dose-Response Relationship, Drug; Kidney Cortex; Kid | 2012 |
Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.
Topics: Arginine; Cardiovascular Diseases; Carotid Intima-Media Thickness; Demography; Female; Humans; Indon | 2012 |
Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end‑stage renal disease treated with hemodialysis.
Topics: Arginine; Biomarkers; Echocardiography; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricu | 2012 |
Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.
Topics: Animals; Antibodies; Arginine; Autoantibodies; Blood Urea Nitrogen; Creatinine; Glomerulonephritis; | 2002 |
Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
Topics: Arginine; Cardiovascular Diseases; Endothelium, Vascular; Humans; Kidney Failure, Chronic; Models, C | 2002 |
Reduction of total homocysteine levels by oral folic acid fails to improve endothelial function in children with chronic renal failure.
Topics: Administration, Oral; Arginine; Child; Endothelium, Vascular; Folic Acid; Homocysteine; Humans; Kidn | 2003 |
[Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
Topics: Adult; Arginine; Chromatography, High Pressure Liquid; Female; Humans; Hypertension; Kidney Failure, | 2002 |
ADMA: a critical cardio-renal link in heart failure?
Topics: Arginine; Heart Failure; Humans; Kidney Failure, Chronic; Nitric Oxide | 2003 |
Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease.
Topics: Adult; Aged; Arginine; Dinoprost; F2-Isoprostanes; Female; Humans; Kidney Failure, Chronic; Liver Di | 2003 |
Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Topics: Aged; Arginine; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cross-Sectional Studi | 2003 |
Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
Topics: Arginine; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Norepinephr | 2004 |
Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency.
Topics: Arginine; Arteriosclerosis; Blotting, Western; Cell Culture Techniques; Endothelial Cells; Enzyme In | 2004 |
Atherosclerosis and uremic retention solutes.
Topics: Arginine; Arteriosclerosis; Female; Glomerulosclerosis, Focal Segmental; Humans; Hyperhomocysteinemi | 2004 |
Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique.
Topics: Adult; Aged; Arginine; Calibration; Carbon Isotopes; Chromatography, Liquid; Citrulline; Female; Hum | 2004 |
Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients.
Topics: Arginine; Arteries; Endothelium, Vascular; Female; Humans; Kidney Failure, Chronic; Male; Middle Age | 2005 |
Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.
Topics: Adult; Aged; Arginine; Arteriosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; En | 2005 |
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Topics: Adult; Arginine; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Hemoglobins; H | 2005 |
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular System; Cohort Studies; Dialysis; Dis | 2005 |
The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
Topics: Adult; Aged; Amino Acid Substitution; Analysis of Variance; Arginine; Aspartic Acid; Cardiovascular | 2005 |
Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA?
Topics: Arginine; Chromatography, Liquid; Enzyme-Linked Immunosorbent Assay; Humans; Hypercholesterolemia; H | 2005 |
Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis.
Topics: Aged; Arginine; Atherosclerosis; beta 2-Microglobulin; Biomarkers; Female; Hospitalization; Humans; | 2005 |
Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease.
Topics: Aged; Arginine; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Female; Gene Frequency; | 2005 |
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.
Topics: Arginine; Atherosclerosis; Biomarkers; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Imm | 2006 |
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Topics: Adenoviridae; Amidohydrolases; Animals; Arginine; Cholesterol; Hypertension; Kidney; Kidney Failure, | 2006 |
Letter by Kielstein et al regarding article, "Renal function as a predictor of outcome in a broad spectrum of patients with heart failure".
Topics: Angiotensin-Converting Enzyme Inhibitors; Arginine; Cardiac Output, Low; Creatinine; Disease Progres | 2006 |
Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
Topics: Arginine; Atherosclerosis; Cardiovascular Diseases; Comorbidity; Female; Homocysteine; Humans; Kidne | 2006 |
Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
Topics: Adult; Arginine; Carotid Artery Diseases; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged | 2006 |
Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunction in rats with chronic renal failure.
Topics: Acetylcholine; Administration, Oral; Animals; Aorta; Arginine; Biopterins; Blood Pressure; Calcimyci | 2007 |
Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry.
Topics: Adolescent; Arginine; Biomarkers; Case-Control Studies; Child; Chromatography, High Pressure Liquid; | 2007 |
Lowering asymmetric dimethylarginine--a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients?
Topics: Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2007 |
Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients.
Topics: Adult; Arginine; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Female; Glycation End | 2008 |
Urotensin II and cardiomyopathy in end-stage renal disease.
Topics: Adult; Aged; Arginine; Cardiomyopathies; Cardiotonic Agents; Echocardiography; Female; Heart Atria; | 2008 |
Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Topics: Amidohydrolases; Animals; Arginine; Base Sequence; Cells, Cultured; DNA Primers; Endothelial Cells; | 2008 |
Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients.
Topics: Aged; Arginine; Biomarkers; Blood Pressure Determination; Case-Control Studies; Female; Follow-Up St | 2008 |
Accumulation of the endogenous L-arginine analogue NG-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis.
Topics: Adult; Arginine; Biological Transport; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Eryt | 1996 |
Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period.
Topics: Adult; Arginine; Blood Pressure; Blotting, Western; Enzyme Inhibitors; Female; Humans; Hypotension; | 1999 |
Determination of asymmetrical dimethylarginine by capillary electrophoresis-laser-induced fluorescence.
Topics: Arginine; Calibration; Electrophoresis, Capillary; Fluorescence; Humans; Kidney Failure, Chronic; La | 2000 |
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
Topics: Adult; Aged; Amino Acids; Arginine; Blood Pressure; Case-Control Studies; Creatinine; Female; Humans | 2001 |
Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.
Topics: Adult; Aged; Arginine; beta 2-Microglobulin; Biocompatible Materials; Blood Pressure; Diabetic Nephr | 2001 |
Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease.
Topics: Anemia; Arginine; Erythropoietin; Hematocrit; Hemoglobins; Humans; Hypotension; Kidney Failure, Chro | 2001 |
Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease.
Topics: Adult; Aged; Arginine; Blood Physiological Phenomena; Blood Urea Nitrogen; Cells, Cultured; Creatini | 2001 |
Dimethylarginines in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Chromatography, High Pressure Liquid; Female; Humans; Kidn | 2001 |
Effect of asymmetric dimethylarginine on osteoblastic differentiation.
Topics: Alkaline Phosphatase; Animals; Arginine; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; F | 2001 |
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
Topics: Adult; Arginine; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hy | 2002 |
Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.
Topics: Adult; Aged; Arginine; C-Reactive Protein; Carotid Arteries; Cohort Studies; Female; Follow-Up Studi | 2002 |
Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin.
Topics: Adult; Aged; Arginine; Endothelin-1; Female; Humans; Hypertension, Renal; Hypotension; Kidney Failur | 2002 |
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
Topics: Adult; Aged; Arginine; Echocardiography; Endothelium, Vascular; Female; Humans; Hypertrophy, Left Ve | 2002 |
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.
Topics: Adult; Animals; Aorta; Arginine; Blood Pressure; Cells, Cultured; Chromatography, High Pressure Liqu | 1992 |